CN1646165A - 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗 - Google Patents
过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗 Download PDFInfo
- Publication number
- CN1646165A CN1646165A CNA028072081A CN02807208A CN1646165A CN 1646165 A CN1646165 A CN 1646165A CN A028072081 A CNA028072081 A CN A028072081A CN 02807208 A CN02807208 A CN 02807208A CN 1646165 A CN1646165 A CN 1646165A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- independently
- aryl
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (101)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26439601P | 2001-01-26 | 2001-01-26 | |
US60/264,396 | 2001-01-26 | ||
US32383901P | 2001-09-21 | 2001-09-21 | |
US60/323,839 | 2001-09-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101262331A Division CN1915429B (zh) | 2001-01-26 | 2002-01-25 | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药 |
CN2008100956414A Division CN101297969B (zh) | 2001-01-26 | 2002-01-25 | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1646165A true CN1646165A (zh) | 2005-07-27 |
CN100509058C CN100509058C (zh) | 2009-07-08 |
Family
ID=26950511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028072081A Expired - Lifetime CN100509058C (zh) | 2001-01-26 | 2002-01-25 | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗 |
Country Status (33)
Country | Link |
---|---|
US (5) | US20020151536A1 (zh) |
EP (2) | EP1413331B1 (zh) |
JP (4) | JP4777602B2 (zh) |
KR (1) | KR100596257B1 (zh) |
CN (1) | CN100509058C (zh) |
AR (2) | AR033855A1 (zh) |
AT (2) | ATE374641T1 (zh) |
AU (1) | AU2002247019C1 (zh) |
BR (1) | BR0206654A (zh) |
CA (3) | CA2562982C (zh) |
CL (1) | CL2004001174A1 (zh) |
CY (2) | CY1108000T1 (zh) |
CZ (2) | CZ301871B6 (zh) |
DE (2) | DE60216890T2 (zh) |
DK (2) | DK1353696T3 (zh) |
EC (1) | ECSP11004702A (zh) |
ES (2) | ES2290562T3 (zh) |
HK (2) | HK1056696A1 (zh) |
HU (2) | HUP0303915A3 (zh) |
IL (3) | IL156445A0 (zh) |
ME (1) | MEP27808A (zh) |
MX (1) | MXPA03006725A (zh) |
NO (1) | NO331512B1 (zh) |
NZ (1) | NZ525921A (zh) |
PL (1) | PL208110B1 (zh) |
PT (2) | PT1413331E (zh) |
RS (2) | RS51449B (zh) |
RU (1) | RU2356550C2 (zh) |
SI (2) | SI1353696T1 (zh) |
SK (2) | SK288217B6 (zh) |
TW (1) | TWI337083B (zh) |
WO (1) | WO2002058732A2 (zh) |
ZA (1) | ZA200305693B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102227212A (zh) * | 2008-09-30 | 2011-10-26 | 力奇制药公司 | 新依泽替米贝制剂 |
CN104337785A (zh) * | 2014-11-04 | 2015-02-11 | 万全万特制药江苏有限公司 | 一种含有依折麦布的口腔崩解片及其制备方法 |
CN106310173A (zh) * | 2016-08-24 | 2017-01-11 | 厦门三川利生物科技有限公司 | 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法 |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517916A (ja) * | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療 |
AU2002241956A1 (en) * | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
ATE345793T1 (de) * | 2001-09-21 | 2006-12-15 | Schering Corp | Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption |
WO2003026573A2 (en) * | 2001-09-24 | 2003-04-03 | Merck & Co., Inc. | Screening and selection methods for statin drug combinations |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
NZ569868A (en) * | 2002-09-27 | 2010-01-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
JP4633469B2 (ja) * | 2002-12-16 | 2011-02-16 | キッセイ薬品工業株式会社 | 経口固形医薬 |
WO2004069193A2 (en) * | 2003-02-03 | 2004-08-19 | Thomas Jefferson University | Methods and compositions for inhibiting cholesterol uptake |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
JP2007510659A (ja) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 |
ATE428411T1 (de) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
ATE485267T1 (de) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
EP1723414A4 (en) * | 2004-01-16 | 2008-03-26 | Merck & Co Inc | NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS |
US20070116645A1 (en) * | 2004-02-03 | 2007-05-24 | Steven Farber | Methods and compositions for inhibiting cholesterol uptake |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CN1759834B (zh) * | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
MY148538A (en) | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
EP1919468A4 (en) * | 2005-07-18 | 2010-02-10 | Reliant Pharmaceuticals Inc | TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF |
US7910698B2 (en) | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
WO2007150063A2 (en) * | 2006-06-23 | 2007-12-27 | Cargill Incorporated | Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements |
US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
DK2167069T3 (da) * | 2007-05-23 | 2011-11-21 | Amcol International Corp | Cholesterol-interagerende lagdelte phyllosilikater og fremgangsmåder til at reducere hypercholesterolæmi hos et pattedyr |
WO2009074286A2 (en) | 2007-12-10 | 2009-06-18 | Ratiopharm Gmbh | Pharmaceutical formulation comprising ezetimibe |
CN102333528B (zh) * | 2009-01-26 | 2013-12-18 | 台北医学大学 | 蕨素化合物用于治疗糖尿病及肥胖之用途 |
PL2229938T3 (pl) | 2009-03-13 | 2012-09-28 | Sanovel Ilac Sanayi Ve Ticaret As | Kompozycje ezetymibu |
US9388440B2 (en) | 2009-04-01 | 2016-07-12 | Mylan Laboratories Limited | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe |
TR200904500A2 (tr) | 2009-06-10 | 2009-10-21 | Öner Levent | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
KR102098032B1 (ko) | 2012-09-27 | 2020-04-07 | 교와 가부시키가이샤 | 지질 이상증 치료제 |
KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
CN105213340A (zh) * | 2015-10-29 | 2016-01-06 | 无锡福祈制药有限公司 | 一种依折麦布片及其制备方法 |
JP2017210455A (ja) * | 2016-05-27 | 2017-11-30 | ニプロ株式会社 | エゼチミブ含有医薬組成物 |
EP3437636A1 (en) | 2017-08-02 | 2019-02-06 | Adamed sp. z o.o. | Pharmaceutical composition comprising ezetimibe |
CN109718215A (zh) * | 2017-10-30 | 2019-05-07 | 海南皇隆制药股份有限公司 | 一种依折麦布片 |
KR101983298B1 (ko) * | 2018-06-11 | 2019-05-29 | 연세대학교 산학협력단 | 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물 |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809194A (en) * | 1957-10-08 | Thiadiazine type natriuretic agents | ||
US3108097A (en) * | 1963-10-22 | Ehnojs | ||
US1286A (en) * | 1839-08-13 | Richard else | ||
NL108640C (zh) * | 1958-05-07 | |||
NL127065C (zh) * | 1964-04-22 | |||
NL137318C (zh) * | 1964-06-09 | |||
FI52570C (fi) * | 1969-04-16 | 1977-10-10 | Sumitomo Chemical Co | Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi. |
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (de) * | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
US4148923A (en) * | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
US4179515A (en) * | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
JPS5195049A (en) * | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
US4235896A (en) * | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
US4075000A (en) * | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
US4304718A (en) * | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4576753A (en) * | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
US4472309A (en) * | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4166907A (en) * | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
US4144232A (en) * | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
FR2403078A1 (fr) * | 1977-09-19 | 1979-04-13 | Lafon Labor | Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic |
IT1157365B (it) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | Medicamenti per trattare l'obesita' o ridurre il peso del corpo |
US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4260743A (en) * | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DE3107100A1 (de) * | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
US4500456A (en) * | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
US4784734A (en) * | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4443372A (en) * | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4534786A (en) * | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4595532A (en) * | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
CA1256650A (en) * | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
US4614614A (en) * | 1983-03-28 | 1986-09-30 | Ciba-Geigy Corporation | Process for the manufacture of optically active azetidinones |
US4675399A (en) * | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
WO1985004876A1 (en) * | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
US4576749A (en) * | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229510A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
FR2561916B1 (fr) * | 1984-03-30 | 1987-12-11 | Lafon Labor | Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau |
US4633017A (en) * | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4581170A (en) * | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4576748A (en) * | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
US4620867A (en) * | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
EP0234484B1 (en) * | 1986-02-19 | 1993-10-20 | Sanraku Incorporated | Novel azetidinone derivatives |
GB8607312D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
FR2598146B1 (fr) * | 1986-04-30 | 1989-01-20 | Rech Ind | Nouveau procede de preparation de fibrates. |
DE3621861A1 (de) * | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen |
FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
US4814354A (en) * | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
US5229362A (en) * | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
PH25145A (en) * | 1986-12-15 | 1991-02-19 | Laverne Dwaine Boeck | Process for producing the a10255 complex and corresponding microorganism |
JPS63156788A (ja) * | 1986-12-22 | 1988-06-29 | Sanraku Inc | 光学活性アゼチジノン類 |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
DE3877406T2 (de) * | 1987-04-28 | 1993-06-09 | Fujisawa Astra Ltd | Benzothiazolinon-derivate, ihre herstellung und pharmazeutische zusammensetzung. |
US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US5091525A (en) * | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US4834846A (en) * | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
US5385885A (en) * | 1988-01-15 | 1995-01-31 | Gasic; Gregory P. | Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide |
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
DE3807895A1 (de) * | 1988-03-10 | 1989-09-21 | Knoll Ag | Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker |
GB8813012D0 (en) * | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
US4952689A (en) * | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
CA1340977C (en) * | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US4876365A (en) * | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
FR2640621B1 (fr) * | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
JPH03108490A (ja) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | フォスフォリパーゼa↓2阻害物質 |
US5021461A (en) * | 1989-07-26 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Method of treating diabetes mellitus with bisphenol derivatives |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
JP2640986B2 (ja) * | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | (1′r,3s)―3―(1′―ヒドロキシエチル)―アゼチジン―2―オン又はその誘導体の製造法 |
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
DE69222532T2 (de) | 1991-07-23 | 1998-02-26 | Schering Corp | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
US5412092A (en) * | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
ATE205475T1 (de) * | 1993-07-09 | 2001-09-15 | Schering Corp | Verfahren zur herstellung von azetidinonen |
WO1995001782A2 (en) * | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
FR2730231B1 (fr) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
US5639475A (en) * | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
JP3144624B2 (ja) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
US5612378A (en) * | 1995-06-06 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
FR2738817B1 (fr) * | 1995-09-14 | 1997-10-17 | Adir | Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
EP0904082A4 (en) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES |
US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
IL126979A (en) * | 1996-05-24 | 2000-10-31 | Schering Corp | Antifungal composition with enhanced bioavailability |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
CA2229077C (en) * | 1996-06-12 | 2007-09-25 | Kyowa Hakko Kogyo Co., Ltd. | Lipid metabolism improving agent |
US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
FR2761266B1 (fr) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
ATE530180T1 (de) * | 1997-04-02 | 2011-11-15 | Brigham & Womens Hospital | Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen |
ES2125198B1 (es) * | 1997-05-13 | 1999-11-16 | Vita Invest Sa | Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares. |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
AR016827A1 (es) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
AU9309898A (en) * | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
US6180625B1 (en) * | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
CA2321538A1 (en) * | 1998-03-27 | 1999-10-07 | Dupont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
EP1073643B1 (en) * | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
JP2002533411A (ja) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール エルエルシー | 心臓血管に適用するための組み合わせ |
US6180138B1 (en) * | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6033656A (en) * | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6174665B1 (en) * | 1999-09-10 | 2001-01-16 | Biex, Inc. | Hormone replacement therapy monitoring |
AU1756201A (en) * | 1999-12-08 | 2001-06-18 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US20020132855A1 (en) * | 2000-08-03 | 2002-09-19 | Nelson Edward B. | Use of acetaminophen to prevent and treat arteriosclerosis |
DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
CA2423141A1 (en) * | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
MXPA03005019A (es) * | 2000-12-21 | 2003-09-25 | Avantis Pharma Deutschland Gmb | Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso. |
IL156550A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
AU2002241956A1 (en) * | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
BR0206644A (pt) * | 2001-01-26 | 2004-02-25 | Schering Corp | Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares |
CA2437118A1 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
WO2002072104A2 (en) * | 2001-03-08 | 2002-09-19 | Merck & Co., Inc. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
US7348334B2 (en) * | 2001-04-09 | 2008-03-25 | Dr. Reddy's Laboratories Limited | Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
AU2002308778A1 (en) * | 2001-05-25 | 2002-12-09 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
-
2002
- 2002-01-25 PT PT04000161T patent/PT1413331E/pt unknown
- 2002-01-25 CA CA2562982A patent/CA2562982C/en not_active Expired - Fee Related
- 2002-01-25 JP JP2002559066A patent/JP4777602B2/ja not_active Expired - Lifetime
- 2002-01-25 EP EP04000161A patent/EP1413331B1/en not_active Expired - Lifetime
- 2002-01-25 EP EP02714773A patent/EP1353696B1/en not_active Expired - Lifetime
- 2002-01-25 DE DE60216890T patent/DE60216890T2/de not_active Expired - Lifetime
- 2002-01-25 SK SK50001-2012A patent/SK288217B6/sk not_active IP Right Cessation
- 2002-01-25 AR ARP020100269A patent/AR033855A1/es not_active Application Discontinuation
- 2002-01-25 RS YUP-586/03A patent/RS51449B/sr unknown
- 2002-01-25 AT AT04000161T patent/ATE374641T1/de active
- 2002-01-25 MX MXPA03006725A patent/MXPA03006725A/es active IP Right Grant
- 2002-01-25 ES ES04000161T patent/ES2290562T3/es not_active Expired - Lifetime
- 2002-01-25 AT AT02714773T patent/ATE348649T1/de active
- 2002-01-25 RU RU2003126184/15A patent/RU2356550C2/ru active
- 2002-01-25 SI SI200230471T patent/SI1353696T1/sl unknown
- 2002-01-25 PL PL368653A patent/PL208110B1/pl unknown
- 2002-01-25 NZ NZ525921A patent/NZ525921A/en not_active IP Right Cessation
- 2002-01-25 KR KR1020037009749A patent/KR100596257B1/ko active IP Right Review Request
- 2002-01-25 DE DE60222773T patent/DE60222773T2/de not_active Expired - Lifetime
- 2002-01-25 AU AU2002247019A patent/AU2002247019C1/en active Active
- 2002-01-25 WO PCT/US2002/002009 patent/WO2002058732A2/en active Application Filing
- 2002-01-25 IL IL15644502A patent/IL156445A0/xx unknown
- 2002-01-25 CA CA002434682A patent/CA2434682C/en not_active Expired - Lifetime
- 2002-01-25 BR BR0206654-8A patent/BR0206654A/pt not_active Application Discontinuation
- 2002-01-25 ME MEP-278/08A patent/MEP27808A/xx unknown
- 2002-01-25 HU HU0303915A patent/HUP0303915A3/hu not_active Application Discontinuation
- 2002-01-25 DK DK02714773T patent/DK1353696T3/da active
- 2002-01-25 SK SK948-2003A patent/SK287988B6/sk not_active IP Right Cessation
- 2002-01-25 PT PT02714773T patent/PT1353696E/pt unknown
- 2002-01-25 US US10/057,323 patent/US20020151536A1/en not_active Abandoned
- 2002-01-25 CA CA002563051A patent/CA2563051A1/en not_active Abandoned
- 2002-01-25 DK DK04000161T patent/DK1413331T3/da active
- 2002-01-25 CZ CZ20032030A patent/CZ301871B6/cs not_active IP Right Cessation
- 2002-01-25 HU HU1500186A patent/HU230253B1/hu unknown
- 2002-01-25 RS RSP-2010/0015A patent/RS20100015A/sr unknown
- 2002-01-25 TW TW091101264A patent/TWI337083B/zh not_active IP Right Cessation
- 2002-01-25 CN CNB028072081A patent/CN100509058C/zh not_active Expired - Lifetime
- 2002-01-25 SI SI200230630T patent/SI1413331T1/sl unknown
- 2002-01-25 CZ CZ2010307A patent/CZ309209B6/cs not_active IP Right Cessation
- 2002-01-25 ES ES02714773T patent/ES2274013T3/es not_active Expired - Lifetime
- 2002-05-01 US US10/136,968 patent/US7030106B2/en not_active Expired - Lifetime
-
2003
- 2003-06-15 IL IL156445A patent/IL156445A/en unknown
- 2003-07-23 ZA ZA2003/05693A patent/ZA200305693B/en unknown
- 2003-07-25 NO NO20033355A patent/NO331512B1/no not_active IP Right Cessation
- 2003-12-18 HK HK03109220A patent/HK1056696A1/xx not_active IP Right Cessation
- 2003-12-18 HK HK04106306A patent/HK1063607A1/xx not_active IP Right Cessation
-
2004
- 2004-05-20 CL CL200401174A patent/CL2004001174A1/es unknown
- 2004-11-29 US US10/998,400 patent/US7612058B2/en active Active
-
2005
- 2005-06-22 US US11/158,429 patent/US20060199793A1/en not_active Abandoned
-
2007
- 2007-02-20 CY CY20071100238T patent/CY1108000T1/el unknown
- 2007-05-28 JP JP2007141163A patent/JP4937836B2/ja not_active Expired - Lifetime
- 2007-08-29 US US11/897,227 patent/US20080058306A1/en not_active Abandoned
- 2007-11-12 JP JP2007293724A patent/JP2008088184A/ja active Pending
- 2007-11-28 AR ARP070105283A patent/AR064012A2/es unknown
- 2007-12-03 CY CY20071101535T patent/CY1107045T1/el unknown
-
2008
- 2008-05-13 IL IL191417A patent/IL191417A/en active IP Right Grant
-
2011
- 2011-02-09 EC EC2011004702A patent/ECSP11004702A/es unknown
-
2012
- 2012-01-31 JP JP2012018544A patent/JP2012087149A/ja not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102227212A (zh) * | 2008-09-30 | 2011-10-26 | 力奇制药公司 | 新依泽替米贝制剂 |
CN104337785A (zh) * | 2014-11-04 | 2015-02-11 | 万全万特制药江苏有限公司 | 一种含有依折麦布的口腔崩解片及其制备方法 |
CN106310173A (zh) * | 2016-08-24 | 2017-01-11 | 厦门三川利生物科技有限公司 | 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1646165A (zh) | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗 | |
CN1582168A (zh) | 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合 | |
CN1527707A (zh) | 取代的氮杂环丁烷酮化合物治疗谷甾醇血症的应用 | |
CN1556700A (zh) | 使用甾醇吸收抑制剂治疗或预防脉管炎的方法 | |
CN1658903A (zh) | 用于治疗血管性疾病的固醇吸收抑制剂与血液调节剂的组合 | |
US7053080B2 (en) | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | |
US8236805B2 (en) | Substituted piperazines as CB1 antagonists | |
US20080261942A1 (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
US20060217363A1 (en) | Methods and therapeutic combinations for the treatment of hypercholesterolemia and xanthoma using sterol absorption inhibitors | |
CN1756756A (zh) | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 | |
US20030119796A1 (en) | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women | |
CN1756752A (zh) | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 | |
US20020183305A1 (en) | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | |
US7071181B2 (en) | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors | |
US20100197564A1 (en) | Diaryl morpholines as cb1 modulators | |
CN1756755A (zh) | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 | |
CN1915429A (zh) | 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗 | |
CN1040873C (zh) | 亚芳烷基-1-氮杂环烷烃,它们的盐及其盐和组合物及其应用和制法 | |
US20060287254A1 (en) | Use of substituted azetidinone compounds for the treatment of sitosterolemia | |
EP1911462A2 (en) | Compositions comprising a sterol absorption inhibitor | |
CN1902169A (zh) | 4-联芳基-1-苯基氮杂环丁烷-2-酮 | |
EP1864680A2 (en) | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
CP01 | Change in the name or title of a patent holder |
Address after: new jersey Patentee after: Schering Corporation Address before: new jersey Patentee before: SCHERING CORP (US) |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210603 Address after: new jersey Patentee after: Okanon LLC Address before: new jersey Patentee before: Merck |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20090708 |